Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
SIMVASTATIN
CT Arzneimittel GmbH
SIMVASTATIN
5 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Withdrawn
2009-08-13
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Simvastatin ct 5 mg Film-coated Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg of simvastatin. Each tablet contains 79.5 mg lactose anhydrous. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Oblong, biconvex, yellow tablets with a scoreline on one side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypercholesterolaemia Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipidlowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. Cardiovascular prevention Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy _(see section 5.1)._ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage range is 5-80 mg/day given orally as a single dose in the evening. Adjustments of dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 80 mg/day given as a single dose in the evening. The 80-mg dose is only recommended in patients with severe hypercholesterolaemia and high risk for cardiovascular complications. Hypercholesterolaemia The patient should be placed on a standard cholesterol-lowering diet, and should continue on this diet during treatment with _Simvastatin-CT_. The usual starting dose is Przeczytaj cały dokument